Onco-Innovations CMO Highlights Novel PNKP Inhibitor ONC010 in BioMedWire Podcast

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer therapy that could address significant unmet needs in oncology. In a recent interview on the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed discussed the company's lead drug candidate, ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP).

ONC010's potential lies in its dual selectivity mechanisms. The first, synthetic lethality, is designed to limit the drug's lethal effects to cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins. This means the drug may preferentially kill cancer cells while sparing healthy ones. The second mechanism, nanoparticle delivery, aims to concentrate the drug within tumor tissue, further enhancing its specificity and potentially reducing systemic toxicity.

Preclinical research conducted at the University of Alberta demonstrated that the nano-formulated PNKP inhibitor exhibited single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings support the continued development of ONC010 and underscore its potential as a targeted cancer therapy.

Onco-Innovations holds an exclusive worldwide license to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. The company is dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.

The interview with Dr. Mohamed provides insight into the company's planned first-in-human clinical program for ONC010. If successful, this program could represent a significant step forward in precision oncology, offering a new treatment option for patients with cancers that have lost PTEN or SHP-1 function. Such cancers are often aggressive and resistant to existing therapies, making the need for new approaches urgent.

For more details on Onco-Innovations and its technology, the full press release is available at https://ibn.fm/XgpMR. Additional news and updates can be found in the company's newsroom at https://ibn.fm/ONNVF.

The BioMedWire podcast, part of the Dynamic Brand Portfolio @ IBN, reaches a wide audience of investors, influencers, and industry professionals. BioMedWire focuses on the latest developments in biotechnology, biomedical sciences, and life sciences, delivering breaking news and actionable information. For more information, visit https://www.BioMedWire.com.